Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for argenex SE (ARGX : NSDQ)

• Company Description    argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. Number of Employees: 1,863

• Price / Volume Information    Yesterday's Closing Price: $1,007.07 Daily Weekly Monthly 20 Day Moving Average: 263,761 shares Shares Outstanding: 62.56 (millions) Market Capitalization: $63,003.30 (millions) Beta: 0.47 52 Week High: $1,072.75 52 Week Low: $661.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.46% 17.29% 12 Week 14.64% 12.21% Year To Date 19.75% 6.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL LAARDERHOOGTWEG 25 - AMSTERDAM,P7 1101EB NLD ph: 31-10-703-8441 fax: - aroy@argenx.com http://www.argenx.com

• General Corporate Information    Officers Tim Van Hauwermeiren - Chief Executive Officer and Director Karen Massey - Chief Operating Officer Karl Gubitz - Chief Financial Officer Arjen Lemmen - Vice-President Corporate Development & Strategy Werner Lanthaler - Director Peer Information argenex SE (CORR.) argenex SE (RSPI) argenex SE (CGXP) argenex SE (BGEN) argenex SE (GTBP) argenex SE (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04016X101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 10/29/26 Share - Related Items Shares Outstanding: 62.56 Most Recent Split Date: (:1) Beta: 0.47 Market Capitalization: $63,003.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $7.62 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $29.13 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 33.23% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/29/26

• Fundamental Ratios P/E Current FY Estimate: 34.57 Trailing 12 Months: 38.67 PEG Ratio: 1.04 Price Ratios Price/Book: 7.49 Price/Cash Flow: 47.21 Price / Sales: 11.82 EPS Growth vs. Year Ago Period: 95.72% vs. Previous Quarter: 32.61% Sales Growth vs. Year Ago Period: 59.43% vs. Previous Quarter: 17.44% ROE 06/30/26 - 43.59 03/31/26 - 44.37 12/31/25 - 38.51 ROA 06/30/26 - 36.66 03/31/26 - 37.55 12/31/25 - 32.59 Current Ratio 06/30/26 - 5.12 03/31/26 - - 12/31/25 - 5.23 Quick Ratio 06/30/26 - 4.89 03/31/26 - - 12/31/25 - 4.87 Operating Margin 06/30/26 - 32.19 03/31/26 - 31.31 12/31/25 - 30.42 Net Margin 06/30/26 - 32.19 03/31/26 - 31.31 12/31/25 - 30.42 Pre-Tax Margin 06/30/26 - 32.80 03/31/26 - 31.61 12/31/25 - 30.10 Book Value 06/30/26 - 134.54 03/31/26 - - 12/31/25 - 118.34 Inventory Turnover 06/30/26 - 2.48 03/31/26 - 2.41 12/31/25 - 2.21 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - - 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - - 12/31/25 - 0.00

Powered by Zacks Investment Research ©